crizotinib and Retroperitoneal-Neoplasms

crizotinib has been researched along with Retroperitoneal-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for crizotinib and Retroperitoneal-Neoplasms

Article	Year
Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation. Internal medicine (Tokyo, Japan), 2019, Apr-01, Volume: 58, Issue:7 Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer with ALK mutation, it is reportedly effective for other malignant tumors with ALK mutation. We herein report a case involving a 37-year-old woman with retroperitoneal IMT with ALK mutation, who experienced recurrence after complete resection, in whom crizotinib treatment resulted in complete response. ALK-inhibitor efficacy against malignancies with ALK mutations should be investigated in future. Topics: Adult; Anaplastic Lymphoma Kinase; Crizotinib; DNA Mutational Analysis; DNA, Neoplasm; Female; Humans; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Retroperitoneal Neoplasms; Sarcoma	2019
Retroperitoneal Pseudotumor Induced by Crizotinib Treatment for c-MET exon 14 Skip Mutation NCSLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:8 Topics: Carcinoma, Non-Small-Cell Lung; Crizotinib; Exons; Female; Granuloma, Plasma Cell; Humans; Lung Neoplasms; Middle Aged; Mutation; Retroperitoneal Neoplasms	2019

Article

Year

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.

Internal medicine (Tokyo, Japan), 2019, Apr-01, Volume: 58, Issue:7

Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer with ALK mutation, it is reportedly effective for other malignant tumors with ALK mutation. We herein report a case involving a 37-year-old woman with retroperitoneal IMT with ALK mutation, who experienced recurrence after complete resection, in whom crizotinib treatment resulted in complete response. ALK-inhibitor efficacy against malignancies with ALK mutations should be investigated in future.

Topics: Adult; Anaplastic Lymphoma Kinase; Crizotinib; DNA Mutational Analysis; DNA, Neoplasm; Female; Humans; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Retroperitoneal Neoplasms; Sarcoma

2019

Retroperitoneal Pseudotumor Induced by Crizotinib Treatment for c-MET exon 14 Skip Mutation NCSLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:8

Topics: Carcinoma, Non-Small-Cell Lung; Crizotinib; Exons; Female; Granuloma, Plasma Cell; Humans; Lung Neoplasms; Middle Aged; Mutation; Retroperitoneal Neoplasms

2019